Relay Therapeutics stockholders approve doubling authorized common stock to 300M shares

Relay Therapeutics, Inc.

Shareholders approved amendment to increase authorized common shares from 150M to 300M (93,032,987 for, 758,293 against).
Directors elected: Alexis Borisy, Mark Murcko, Laura Shawver (class II, three-year term).
Non-binding advisory vote on executive compensation passed (83,645,401 for, 3,551,366 against).
Ratification of Ernst & Young as independent auditor for FY2022 approved (93,772,475 for, 15,739 against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.